About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 12800 record(s)
Req # A-2024-000706
Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_06985893, E2B_06463299, E2B_06478815, E2B_07089342, E2B_07139781, E2B_07091591, E2B_06698587, E2B_07133130, E2B_07044870, E2B_07041649.Organization: Health Canada
January 2025
Req # A-2024-000707
Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_07035040, E2B_06899159, E2B_06926857, E2B_06836971, E2B_07168878, E2B_07119993, E2B_07248238, 001083465, E2B_07058290, E2B_07080809.Organization: Health Canada
January 2025
Req # A-2024-000710
Adverse Drug Reactions (ADRs) for Leuprorelin. Report numbers: E2B_06779053, E2B_06907444, E2B_07004123. ADRs for Leuprolide acetate. Report numbers: E2B_07148683, E2B_07154505, E2B_07148672, E2B_06868975, E2B_07148681.Organization: Health Canada
January 2025
Req # A-2024-000755
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-109977-88, Canadian Institute for Health Information Release of Report: “Prescribed Drug Spending in Canada, 2023".Organization: Health Canada
January 2025
Req # A-2024-000756
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-104766-527, Results of Public Opinion Research on Knowledge and Attitudes of Canadians Towards Drug Decriminalization.Organization: Health Canada
January 2025
Req # A-2024-000763
Adverse Drug Reaction (ADR). Report number: E2B_07253848.Organization: Health Canada
January 2025
Req # A-2024-000769
Adverse Drug Reactions (ADRs). Report numbers: E2B_05422984, 001041491, E2B_06352172, E2B_06355840, E2B_06370379, E2B_06390563, E2B_06394985.Organization: Health Canada
January 2025
Req # A-2024-000784
From May 29, 2023 to September 23, 2024, provide the HC procedures and protocols for the analysis of substances that may contain metonitazene. I am not requesting versions or drafts before May 29, 2023.Organization: Health Canada
January 2025
Req # A-2024-000787
Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_07270577, E2B_07290183, E2B_07292296, 001102535, E2B_07290569, E2B_07315569, E2B_07285367. ADRs for Mesalamine. Report numbers: E2B_07276842, E2B_07305609, E2B_07289987.Organization: Health Canada
January 2025
Req # A-2024-000791
Adverse Drug Reaction (ADR) for Ondansetron. Report number: E2B_07292203.Organization: Health Canada
January 2025